phone

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • Published Date: 01 May 2017
  • Number of Pages: 280
  • Category: Healthcare and Medical
  • Country: Global
OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Summary

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered

- How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in ovarian cancer?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the unmet needs in ovarian cancer treatment management?
- What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

- Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Publisher Name : GlobalData

2 Ovarian Cancer: Executive Summary 10
2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025 10
2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers 12
2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MMs Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizers First-to-Market Bavencio 13
2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining 14
2.5 What Do Physicians Think? 16
3 Introduction 20
3.1 Catalyst 20
3.2 Related Reports 21
3.3 Upcoming Related Reports 21
4 Disease Overview 22
4.1 Etiology and Pathophysiology 22
4.2 Staging Systems 23
4.3 Risk Factors, Symptoms, and Screening 24
4.4 Prognosis and Quality of Life 26
5 Epidemiology 28
5.1 Disease Background 28
5.2 Risk Factors and Comorbidities 28
5.3 Global Trends 30
5.3.1 7MM Incidence Trends 30
5.3.2 7MM Trends in Relative Survival 30
5.4 Forecast Methodology 31
5.4.1 Sources Used Tables 31
5.4.2 Forecast Assumptions and Methods 32
5.4.3 Sources Not Used 34
5.5 Epidemiological Forecast for Ovarian Cancer (2015-2025) 35
5.5.1 Diagnosed Incident Cases of Ovarian Cancer 35
5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer 37
5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer 38
5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer 39
5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer 41
5.6 Discussion 42
5.6.1 Epidemiological Forecast Insight 42
5.6.2 Limitations of the Analysis 42
5.6.3 Strengths of the Analysis 43
6 Current Treatment Options 44
6.1 Overview 44
6.2 Diagnosis and Treatment 44
6.2.1 Diagnosis 44
6.2.2 Treatment Guidelines 45
6.3 Clinical Practice and Leading Prescribed Drugs 46
6.4 Product Profiles - Major Brands, Angiogenesis Inhibitors 50
6.4.1 Avastin (bevacizumab) 50
6.5 Product Profiles - Major Brands, PARP Inhibitors 59
6.5.1 Lynparza (olaparib) 60
6.5.2 Rubraca (rucaparib) 70
6.5.3 Zejula (niraparib) 75
6.6 Product Profiles - Major Brands, Next-Generation Chemotherapies 81
6.6.1 Yondelis (trabectedin) 81
6.7 Generic Chemotherapy 87
6.7.1 Front-Line Treatment (Adjuvant/First Line) 87
6.7.2 Recurrent Disease 92
7 Unmet Needs Assessment and Opportunity Analysis 95
7.1 Overview 95
7.2 Improved First-line Therapies 96
7.2.1 Unmet Need 96
7.2.2 Gap Analysis 96
7.2.3 Opportunity 99
7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients 99
7.3.1 Unmet Need 99
7.3.2 Gap Analysis 100
7.3.3 Opportunity 101
7.4 Individualized Treatment Approaches 102
7.4.1 Unmet Need 102
7.4.2 Gap Analysis 102
7.4.3 Opportunity 104
7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer 104
7.5.1 Unmet Need 104
7.5.2 Gap Analysis 105
7.5.3 Opportunity 105
7.6 An Early Stage Diagnostic for Ovarian Cancer 105
7.6.1 Unmet Need 105
7.6.2 Gap Analysis 106
7.6.3 Opportunity 106
8 Research and Development Strategies 107
8.1 Overview 107
8.1.1 Optimizing Chemotherapy 108
8.1.2 Targeted Therapies - A Patient Specific Approach 109
8.1.3 Immunotherapies - A Patient Specific Approach 114
8.1.4 Combination Therapies 116
8.1.5 Licenses and Alliances 117
8.2 Clinical Trial Design 118
8.2.1 Current Clinical Trial Endpoints 120
8.2.2 The Future of Clinical Trial Endpoints 120
8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials 121
9 Pipeline Assessment 124
9.1 Overview 124
9.2 Product Profiles - Immune Checkpoint Modulators 126
9.2.1 Bavencio (avelumab) 128
9.2.2 Opdivo (nivolumab) 134
9.2.3 Tecentriq (atezolizumab) 139
9.3 Product Profiles - Cancer Vaccines 144
9.3.1 Vigil (gemogenovatucel-T) 144
9.4 Product Profiles - Vascular Disrupting Agents 150
9.4.1 Fosbretabulin tromethamine 150
9.5 Product Profiles - PARP Inhibitors 155
9.5.1 Veliparib 157
9.6 Product Profiles - Targeted Cytotoxic Therapies (Antibody-Drug Conjugates) 163
9.6.1 Mirvetuximab soravtansine 163
9.7 Product Profiles - Next-Generation Chemotherapies 168
9.7.1 Opaxio (paclitaxel poliglumex) 168
9.7.2 Lurbinectedin 174
9.7.3 Apealea/Paclical (paclitaxel) 178
9.8 Innovative Early Stage Approaches 182
9.8.1 Immune Checkpoint Modulators 183
9.8.2 Oncolytic Viruses 188
9.8.3 Angiogenesis Inhibitors 191
9.8.4 Interleukin-12 Agonists 194
9.8.5 Toll-Like Receptor 8 Agonists 195
9.8.6 Cancer Vaccines 196
9.8.7 Kinase Inhibitors 199
9.8.8 Targeted Cytotoxic Therapies 203
9.8.9 P53 Agonists 203
9.9 Other Notable Drugs in Clinical Development 204
10 Pipeline Valuation Analysis 206
10.1 Clinical Benchmark of Key Pipeline Products 206
10.2 Commercial Benchmark of Key Pipeline Therapies 209
10.3 Competitive Assessment 210
10.4 Top-Line Ten-Year Forecast 212
10.4.1 US 216
10.4.2 5EU 217
10.4.3 Japan 218
11 Appendix 220
11.1 Bibliography 220
11.2 Abbreviations 247
11.3 Methodology 254
11.4 Forecasting Methodology 254
11.4.1 Percentage of Drug-Treated Patients 255
11.4.2 Drugs Included in Each Therapeutic Class 256
11.4.3 Launch and Patent Expiry Dates 256
11.4.4 General Pricing Assumptions 257
11.4.5 Average Body Weight and Surface Area Across the 7MM 258
11.4.6 General Forecast Assumptions 258
11.4.7 Individual Drug Assumptions 259
11.4.8 Generic and Biosimilar Erosion 266
11.4.9 Pricing of Pipeline Agents 266
11.5 Primary Research 274
11.5.1 Physicians and Specialists Included in This Study 274
11.5.2 Online Survey of High-Prescribing Physicians 276
11.6 About the Authors 277
11.6.1 Analysts 277
11.6.2 Epidemiologist 278
11.6.3 Therapy Area Director 278
11.6.4 Global Director of Therapy Analysis and Epidemiology 278
11.6.5 Global Head of Healthcare 279
11.7 About GlobalData 279
11.8 Contact Us 280
11.9 Disclaimer 280

List Of Tables


Table 1: Ovarian Cancer: Key Metrics in the 7MM 10
Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum 24
Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016 26
Table 4: Risk Factors of OC 29
Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC 31
Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC 32
Table 7: 7MM, Diagnosed Incident Cases of OC, Ages 18 Years, N, 2015-2025 35
Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 37
Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages 18 Years, N, 2015-2025 40
Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages 18 Years, N, 2015-2025 41
Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM 45
Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease 49
Table 13: Product Profile - Avastin 51
Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 56
Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer 57
Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer 57
Table 17: Grade 3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer 58
Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017 58
Table 19: Product Profile - Lynparza 61
Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial 65
Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer 66
Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer 67
Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19 68
Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017 69
Table 25: Product Profile - Rubraca 70
Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer 73
Table 27: Most Common AEs Reported in 20% of Patients in Study 10 and ARIEL2 74
Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017 74
Table 29: Product Profile - Zejula 76
Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer 79
Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula 80
Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017 81
Table 33: Product Profile - Yondelis 82
Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer 85
Table 35: Most Commonly Reported Grade 3 and 4 AEs in 5% of Patients in OVA-301 86
Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017 87
Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer 88
Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer 89
Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer 90
Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment 91
Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer 94
Table 42: Unmet Needs and Opportunities in Ovarian Cancer 96
Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer. 118
Table 44: Potential New Classification System for Recurrent Ovarian Cancer 123
Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017 125
Table 46: Product Profile - Bavencio 129
Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 132
Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 132
Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 133
Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 133
Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017 134
Table 52: Product Profile - Opdivo 135
Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714) 137
Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo 138
Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017 139
Table 56: Product Profile - Tecentriq 140
Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017 144
Table 58: Product Profile - Vigil (gemogenovatucel-T) 146
Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial 149
Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials 149
Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017 150
Table 62: Product Profile - Fosbretabulin Tromethamine 152
Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer 154
Table 64: Grade 2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer 154
Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017 155
Table 66: Product Profile - Veliparib 158
Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 161
Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial 162
Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017 162
Table 70: Product Profile - Mirvetuximab soravtansine 164
Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FR+ Ovarian Cancer 166
Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FR+ Ovarian Cancer 167
Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017 167
Table 74: Product Profile - Opaxio 169
Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer 172
Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer 173
Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017 173
Table 78: Product Profile - Lurbinectedin 174
Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer 177
Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer 177
Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017 178
Table 82: Product Profile - Apealea 179
Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer 181
Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer 181
Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017 182
Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017 183
Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy 184
Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda 185
Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab 186
Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat 187
Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab 188
Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin 189
Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev 190
Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer 193
Table 95: Summary of Grade 3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer 194
Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017 194
Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1 195
Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod 196
Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac 197
Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa 198
Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac 199
Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib 200
Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef 201
Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib 202
Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib 203
Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027 203
Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246 204
Table 108: Other Notable Ovarian Cancer Products in Development, 2017 205
Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products 207
Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued 207
Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products 210
Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued 210
Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015-2025 ($M) 213
Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015-2025 215
Table 115: Ovarian Cancer Products Market - Drivers and Barriers, 2015-2025 216
Table 116: Ovarian Cancer Patient Population segmentations in the 7MM - Secondary Sources Leveraged 255
Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class 256
Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM 256
Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM 257
Table 120: Average Body Weight and Surface Area Across the 7MM 258
Table 121: Average Cost of Therapy of Avastin in the 7MM 261
Table 122: Average Cost of Therapy of Lynparza in the 7MM 263
Table 123: Average Cost of Therapy of Rubraca in the US and 5EU 264
Table 124: Average Cost of Therapy of Yondelis in the 7MM 265
Table 125: Average Cost of Therapy of Votrient in the 7MM 265
Table 126: Average Cost of Therapy of Zejula in the US and 5EU 266
Table 127: Average Cost of Therapy of Veliparib in the 7MM 267
Table 128: Average Cost of Therapy of Bavencio in the 7MM 268
Table 129: Average Cost of Therapy of Tecentriq in the 7MM 269
Table 130: Average Cost of Therapy of Opdivo in the 7MM 270
Table 131: Average Cost of Therapy of Vigil in the 7MM 270
Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM 271
Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU 272
Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM 273
Table 135: Average Cost of Therapy of Apealea in the US and 5EU 274
Table 136: High-Prescribing Physicians Surveyed, by Country 277

List Of Figures


Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025 12
Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 15
Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms 23
Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer 25
Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 19982007 30
Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages 18 Years, N, 2015-2025 36
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 38
Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages18 Years, Cases per 100,000, 2015 39
Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages 18 Years, N, 2015-2025 40
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages 18 Years, N, 2015-2025 42
Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients 48
Figure 12: Clinical Development Program for Avastin in Ovarian Cancer 53
Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer 63
Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer 72
Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer 78
Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer 83
Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer 131
Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer 136
Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer 142
Figure 20: Clinical Development Program for Vigil in Ovarian Cancer 148
Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer 153
Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer 160
Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer 165
Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer 170
Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer 175
Figure 26: Clinical Development Program for Apealea in Ovarian Cancer 180
Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer 192
Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 211
Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025 214

OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver

View Report

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due

View Report

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Immune Thrombocytopenia (ITP) is an auto-immune-related bleeding disorder characterized by a low platelet count. Patients with severe ITP often experience

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports